PHENOBARBITAL
Aside
from the bromides, phenobarbital is the oldest of the currently available
antiseizure drugs. Although it has long been considered one of the safest of
the antiseizure agents, the use of other medications with lesser sedative
effects has been urged. Many consider the barbi-turates the drugs of choice for
seizures only in infants.
The
four derivatives of barbituric acid clinically useful as antisei-zure drugs are
phenobarbital, mephobarbital, metharbital, and primidone. The first three are
so similar that they are considered together. Metharbital is methylated
barbital, and mephobarbital is methylated phenobarbital; both are demethylated
in vivo. The pKas of these three weak acid compounds range from 7.3
to 7.9. Slight changes in the normal acid-base balance, therefore, can cause
significant fluctuation in the ratio of the ionized to the non-ionized species.
This is particularly important for phenobarbital, the most commonly used
barbiturate, whose pKa is similar to the plasma pH of 7.4.
The
three-dimensional conformations of the phenobarbital and N-methylphenobarbital molecules are similar to that of phe-nytoin.
Both compounds possess a phenyl ring and are active against partial seizures.
The
exact mechanism of action of phenobarbital is unknown, but enhancement of
inhibitory processes and diminution of excitatory transmission probably
contribute significantly. Recent data indicate that phenobarbital may
selectively suppress abnormal neurons, inhibiting the spread and suppressing
firing from the foci. Like phenytoin, phenobarbital suppresses high-frequency
repetitive fir-ing in neurons in culture through an action on Na+
conductance, but only at high concentrations. Also at high concentrations,
barbi-turates block some Ca2+ currents (L-type and N-type).
Phenobarbital binds to an allosteric regulatory site on the GABAA
receptor, and it enhances the GABA receptor-mediated current by prolonging the
openings of the Cl– channels . Phenobarbital can also decrease
excitatory responses. An effect on glutamate release is probably more
significant than blockade of AMPA responses . Both the enhancement of
GABA-mediated inhibition and the reduction of glutamate-mediated excitation are
seen with therapeutically relevant concentrations of phenobarbital.
Phenobarbital
is useful in the treatment of partial seizures and generalized tonic-clonic
seizures, although the drug is often tried for virtually every seizure type,
especially when attacks are difficult to control. There is little evidence for
its effectiveness in general-ized seizures such as absence, atonic attacks, and
infantile spasms; it may worsen certain patients with these seizure types.Some
physicians prefer either metharbital (no longer readily available) or
mephobarbital (especially the latter) to phenobarbital because of supposed
decreased adverse effects. Only anecdotal data are available to support such
comparisons.
For
pharmacokinetics, drug interactions, and toxicity of pheno-barbital.The
therapeutic levels of phenobarbital in most patients range from 10 mcg/mL to 40
mcg/mL. Documentation of effectiveness is best in febrile seizures, and levels
below 15 mcg/mL appear inef-fective for prevention of febrile seizure
recurrence. The upper end of the therapeutic range is more difficult to define
because many patients appear to tolerate chronic levels above 40 mcg/mL.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.